Russian Trials Test Drug For Preventing Age-Related Dry-Eye Disease
This article was originally published in PharmAsia News
Russian researchers are moving through clinical trials for Visomitin (skulachev ions) for preventing age-related dry-eye diseases.
You may also be interested in...
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.